Olema Pharmaceuticals (OLMA) Institutional Ownership

91.78% of Olema Pharmaceuticals' stock is owned by institutional investors. Learn more on OLMA's institutional investor holdings.

Of the 168 institutional investors that purchased Olema Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Bain Capital Life Sciences Investors LLC ($9.13M), Siren L.L.C. ($4.76M), Point72 Asset Management L.P. ($3.69M), Janus Henderson Group PLC ($3.52M), Cormorant Asset Management LP ($2.75M), RA Capital Management L.P. ($2.60M), and Paradigm Biocapital Advisors LP ($2.58M).

Institutional investors have bought a total of 34,137,322 shares in the last 24 months. This purchase volume represents approximately $737.96M in transactions.

Of the 40 institutional investors that sold Olema Pharmaceuticals' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Pictet Asset Management Holding SA ($1.42M), Woodline Partners LP ($1.29M), UBS Group AG ($1.12M), Millennium Management LLC ($939.64K), Vivo Capital LLC ($834.02K), Pier Capital LLC ($677.86K), and MPM Bioimpact LLC ($551.68K).

Institutional investors have sold a total of 9,877,818 shares in the last 24 months. This volume of shares sold represents approximately $160.79M in transactions.